A high-angle, organized flat lay of pharmaceutical supplies on a white background, including a syringe, a large blister pack of white pills, a row of capsules, sterile needles, and loose orange tablets.
Report

Strengthening the US-Mexico Pharmaceutical Supply Chain

Portrait of Matthew Aleshire

Matthew Aleshire

Director, Geo-Economics
Matthew Aleshire is director on the Milken Institute’s Geo-Economics Initiative and helps to lead the work around the topics of climate change, the global financial architecture, and international political economy. Aleshire previously focused on global policy and government engagement for the Milken Institute, overseeing efforts to advance policy solutions across the Institute’s research and convenings.
Professional headshot of Christina Dialynas, a woman with long dark brown wavy hair, wearing a navy ribbed top and a gold chain necklace. She is smiling gently and posed against a dark gray background.

Christina (Dialynas) Pecherer

Director, Public Health, Milken Institute Health
Christina (Dialynas) Pecherer's work on the Public Health team at the Milken Institute involves researching improvements in mental health access, workplace engagement, youth mental health in the digital age, and pharmaceutical supply chain resilience, among other topics.
Topics
Health
Health Care Delivery
Supply Chains and Health Care
Public Health
Resource Downloads
Download Report
Stay informed by the Milken Institute

The pharmaceutical supply chain is an intricate, interconnected system that plays a crucial role in ensuring communities and individuals have timely access to medicines. However, critical medicine shortages increasingly threaten public health systems worldwide, and much of North America’s pharmaceutical supply chain relies heavily on countries outside the Americas, putting its resiliency and security at risk. Against the backdrop of trade-related uncertainty and the vulnerabilities exposed by overdependence on a limited number of suppliers, countries and companies alike are seeking to diversify their supply chains.

Mexico faces a unique opportunity to strengthen and expand its role in the global pharmaceutical supply chain due to its proximity to the US, its strong pharmaceutical industry, and the framework of the United States-Mexico-Canada Agreement.

The Milken Institute convened pharmaceutical, finance, and government leaders at the 2025 Milken Institute Investors’ Symposium in Mexico City to ideate a path toward enhancing Mexico’s competitiveness in the global pharmaceutical supply chain. This brief summarizes the learnings and takeaways from the experts in the room and highlights the critical importance of a safe and secure pharmaceutical supply chain.

Related Content